Core Insights - Autonomix Medical, Inc. is focused on innovative technologies for diagnosing and treating diseases of the nervous system [3][4] - The company will present at the LSI USA '25 Emerging Medtech Summit on March 18, 2025 [1][2] - Autonomix's technology includes a catheter-based microchip sensing array with approximately 3,000 times greater sensitivity than current technologies [3] Company Overview - Autonomix Medical, Inc. specializes in medical devices aimed at revolutionizing the diagnosis and treatment of nervous system diseases [3] - The company's platform technology is designed for transvascular diagnosis and treatment of peripheral nervous system diseases [3][4] - Initial development focuses on pain treatment, particularly for pancreatic cancer, which currently lacks reliable solutions [4] Technology and Applications - The technology is investigational and not yet cleared for marketing in the United States [4] - The platform has potential applications across various medical fields, including cardiology, hypertension, and chronic pain management [4]

Core Viewpoint - Autonomix Medical, Inc. is set to present its innovative catheter-based technology and initial findings from a clinical trial focused on treating pain in pancreatic cancer patients at the upcoming CRT Annual Meeting in March 2025 [1][2]. Company Overview - Autonomix is a medical device company dedicated to advancing technologies for diagnosing and treating diseases related to the nervous system [3]. - The company's platform technology features a catheter-based microchip sensing array that can detect and differentiate neural signals with approximately 3,000 times greater sensitivity than existing technologies [3]. - The initial focus of this technology is on pain management, particularly for pancreatic cancer, which is known for causing severe pain and lacks effective treatment options [4]. Clinical Presentation Details - The presentation titled "Catheter-Based Transvascular RF Neural Ablation For Severe Pancreatic Cancer Pain: First Results From The Elpis Study" will be delivered by Dr. Robert Schwartz, Chief Medical Officer of Autonomix [2]. - The session is scheduled for March 10, 2025, from 2:00 PM to 2:40 PM ET during the Innovation HUB session at the CRT Annual Meeting [2]. Technology Potential - The technology has the potential to revolutionize the treatment of various conditions involving the peripheral nervous system, with applications extending beyond pancreatic cancer to areas such as cardiology, hypertension, and chronic pain management [4].

On-demand video webcast now available here THE WOODLANDS, TX, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced it participated in the Virtual Investor “Top 5 for ‘25” On-Demand Conference. As part of the event, Brad Hauser, President and Chief Executive Officer of Autonomix, presented the top five reasons of why he believes the investment community and in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 Autonomix Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 001-41940 47-1607810 (Commission File Number) (I.R.S. Employer Identification No.) 21 Waterway Avenue, Suite 300 The Woodlands ...

Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer with topline data on track for 1H 2025 Continued solid execution on milestones with several design locks and key development objectives met in the quarter Company remains on track to submit an Investigational Device Exemption (“IDE”), and if approved, will initiate US clinical trials in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NAS ...

Design lock for ASIC microchip follows successful completion of in vivo preclinical and extensive bench testing Manufacturing of ASIC microchip for targeted use in humans has been initiated Company advancing toward submitting Investigational Device Exemption (“IDE”), and if approved, will commence a pivotal clinical trial to support a De Novo application for FDA approval THE WOODLANDS, TX, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical dev ...

THE WOODLANDS, TX, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced its abstract has been accepted for poster presentation at the SIO 2025 Annual Scientific Meeting, being held January 30 – February 3, 2025 in Las Vegas, NV. Details of the accepted abstract are as follows: Title: Abla ...

Growing global patent portfolio to over 120 patents with 80 issued patents and over 40 pending patent applications Previously completed preclinical study evaluating targeted nerve ablation demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass THE WOODLANDS, TX, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutio ...

Core Viewpoint - Autonomix Medical, Inc. has developed innovative technologies aimed at revolutionizing the diagnosis and treatment of diseases involving the nervous system, with a focus on pancreatic cancer-related pain management [2][4]. Group 1: Patent and Technology Development - The company has a growing global patent portfolio with over 120 patents, including 80 issued patents and over 40 pending applications [3][5]. - The recently issued U.S. patent 12,064,256 (the "256 patent") covers systems and methods for treating cancer and augmenting organ function, specifically targeting pancreatic cancer-related pain [3][4]. - Autonomix's first-in-class catheter-based microchip sensing array technology can detect and differentiate neural signals with approximately 3,000 times greater sensitivity than existing technologies [2][6]. Group 2: Clinical Studies and Results - A preclinical study demonstrated a statistically significant reduction in metastases and tumor mass through targeted nerve ablation, indicating the potential impact of neural pathways in pancreatic cancer [4][6]. - The ongoing proof-of-concept human clinical trial is focused on pain reduction from the ablation of target nerves near the pancreas, with plans for additional studies to evaluate the clinical application of the technology [4][10]. Group 3: Future Directions and Applications - The company aims to explore the potential of its ablation technology to slow pancreatic cancer growth and metastasis based on positive preclinical results [4][10]. - The technology platform is designed to address various disease categories, including chronic pain management, cardiology, and hypertension, beyond its initial focus on cancer pain [10].

Continued efforts to build team and infrastructure required to support clinical and regulatory initiatives in anticipation of the FDA approval process for first-in-class catheter-based sensing technology Company remains on track to submit an Investigational Device Exemption ("IDE"), and if approved, will commence a pivotal clinical trial in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX , Dec. 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "C ...